Sylvia Streit

TL;DR: A broad overview of signal transduction networks that are controlled by the EGFR superfamily of receptors in health and disease and its application for target-selective therapeutic intervention is given.

TL;DR: FGFR4 contributes significantly to HCC progression by modulating AFP secretion, proliferation and anti-apoptosis and its inhibition a novel and much needed pharmacological approach against HCC.

TL;DR: The results show that the previously found association of FGFR4 Arg388 genotype with breast cancer progression is strongest in patients with adjuvant systemic therapy, particularly chemotherapy, and thus may reflect therapy resistance.

TL;DR: Investigation of the expression pattern of FGFR4 and the clinical significance of the recently identified Gly/Arg polymorphism in head and neck squamous cell carcinomas (HNSCCs) of the oral cavity and the oropharynx indicates that high expression ofFGFR4 in connection with the Arg388 allele is associated with poor clinical outcome and supports the significance of FG FR4 as a diagnostic marker and a target for therapeutic intervention in human HNSCC.

TL;DR: The approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumours are the first examples of gene-based cancer drugs and represent the first example of a novel strategy in anti-cancer therapy.